STOCK TITAN

Chemomab Therapeutics Ltd - CMMB STOCK NEWS

Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company pioneering the development of innovative therapies for fibro-inflammatory diseases with significant unmet medical needs. Based in Tel Aviv, Israel, Chemomab's research focuses on addressing the underlying mechanisms of fibrosis and inflammation, conditions that contribute to a range of severe and life-threatening diseases. The company's lead therapeutic candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize the soluble protein CCL24, a key regulator of inflammatory and fibrotic pathways.

Core Therapeutic Focus and Mechanism of Action

Nebokitug (CM-101) operates through a unique dual mechanism of action, targeting both immune cell recruitment and fibroblast activation. By inhibiting CCL24, nebokitug disrupts the self-perpetuating fibro-inflammatory cycle that drives fibrosis. This approach has shown promise in addressing a variety of fibro-inflammatory diseases, including primary sclerosing cholangitis (PSC), a rare and progressive liver disease, and systemic sclerosis (SSc), a debilitating autoimmune condition affecting the skin, lungs, and other organs.

Clinical Development and Regulatory Milestones

Chemomab has advanced nebokitug through multiple clinical trials, demonstrating its safety, tolerability, and efficacy. The company's Phase 2 SPRING trial in PSC established clinical proof-of-concept, showing improvements across a range of disease biomarkers, including liver stiffness, Enhanced Liver Fibrosis (ELF) scores, and pruritus severity. These results have positioned nebokitug as the first investigative therapy for PSC with broad activity across all major disease components.

In collaboration with the U.S. Food and Drug Administration (FDA), Chemomab recently secured alignment on the design of a single Phase 3 registration trial for nebokitug in PSC. This pivotal trial will evaluate clinically meaningful endpoints, such as time-to-first-event of disease progression, without requiring invasive liver biopsies. This streamlined pathway offers a significant acceleration toward potential full regulatory approval.

Market Position and Competitive Advantages

Chemomab's focus on fibro-inflammatory diseases with high unmet needs provides a strategic advantage in the biotechnology sector. Nebokitug has received Orphan Drug and Fast Track designations from both the FDA and the European Medicines Agency (EMA), underscoring its potential to address critical gaps in treatment. The company's robust intellectual property portfolio, including patents extending to 2038, further strengthens its market position.

With an estimated 30,000 PSC patients in the U.S. and 80,000 worldwide, as well as significant unmet needs in related conditions like systemic sclerosis, Chemomab is well-positioned to capture a substantial share of these markets. Additionally, the company's ongoing discussions with strategic partners could accelerate the development and commercialization of nebokitug across multiple indications.

Future Outlook

Chemomab is preparing to launch its Phase 3 PSC trial in late 2025, with results from the open-label extension of the Phase 2 SPRING trial expected in early 2025. These milestones, coupled with the company's proactive engagement with regulatory authorities and potential biopharma partners, highlight its commitment to delivering transformative therapies. By addressing the root causes of fibro-inflammatory diseases, Chemomab aims to improve patient outcomes and establish itself as a leader in this specialized therapeutic domain.

Key Takeaways

  • Innovative Science: First-in-class monoclonal antibody targeting CCL24, a novel driver of fibrosis and inflammation.
  • Clinical Progress: Positive Phase 2 data in PSC, with Phase 3 trial design aligned with FDA guidance.
  • Regulatory Advantages: Orphan Drug and Fast Track designations for nebokitug in PSC.
  • Market Potential: Addressing high unmet needs in rare fibro-inflammatory diseases.
  • Strategic Partnerships: Active discussions with biopharma companies to accelerate development timelines.
Rhea-AI Summary

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced the appointment of Jack Lawler as Vice President of Global Clinical Development Operations, enhancing its clinical development leadership. Lawler brings over 22 years of experience in drug development, previously contributing to eight approved pharmaceuticals. Chemomab has also expanded its facilities in Tel Aviv to support anticipated growth. The company focuses on developing CM-101, a monoclonal antibody aimed at addressing serious fibrotic and inflammatory diseases, currently in two Phase 2 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) announced participation in two key virtual events: the LifeSci Partners 11th Annual Corporate Access Event from January 5-7, 2022, featuring 1-on-1 meetings, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022, offering an on-demand corporate overview webcast. Chemomab focuses on therapeutics for fibrotic and inflammatory diseases, with its lead candidate, CM-101, in Phase 2 trials targeting multiple severe conditions. For event registration and additional details, visit Chemomab's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
conferences
-
Rhea-AI Summary

Chemomab Therapeutics Ltd (Nasdaq: CMMB) has announced that CEO Dale R. Pfost will take on the role of Chairman, pending shareholder approval expected in February 2022. Stephen Squinto will step down from his role as Chairman and director on December 19, 2021. Dr. Pfost expressed excitement for the company's Phase 2 clinical programs in liver fibrosis and systemic sclerosis. Chemomab is developing CM-101, a monoclonal antibody targeting CCL24, currently undergoing clinical trials for severe fibrotic and inflammatory diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
management
Rhea-AI Summary

Chemomab Therapeutics Ltd. (NASDAQ: CMMB) announced the appointment of David M. Weiner, MD, as Interim Chief Medical Officer, effective immediately. He replaces Dr. Arnon Aharon, who will remain for a 60-day transition period. Dr. Weiner brings over 25 years of biopharmaceutical experience and has held senior roles at various biotech companies. He aims to advance Chemomab's clinical programs, particularly for CM-101, a monoclonal antibody in Phase 2 trials targeting fibrotic diseases. The company acknowledges Dr. Aharon's contributions to its clinical advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.27%
Tags
none
-
Rhea-AI Summary

Chemomab Therapeutics (CMMB) announced its third-quarter financial results for 2021, revealing a significant cash position of $64.3 million, which is expected to fund operations until mid-2023. The company reported a net loss of $3.0 million, or ($0.01) per share, compared to a loss of $1.2 million in the previous year. Key updates included advancements in clinical trials for CM-101 aimed at treating fibrotic diseases and the appointment of Donald Marvin as CFO. Upcoming data readouts from ongoing Phase 2 trials are anticipated in 2022, suggesting potential growth for Chemomab's pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary

Chemomab Therapeutics (Nasdaq: CMMB) announced a poster presentation at The Liver Meeting 2021, showcasing its research on CCL24's role in Primary Sclerosing Cholangitis (PSC). The study highlights the high expression of CCL24 in PSC liver biopsies and the efficacy of the monoclonal antibody CM-101 in reducing liver injury in preclinical models. CM-101 is currently in Phase 2 trials targeting PSC and other fibrotic diseases. The company's advancements provide promising insights into potential treatment avenues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
Rhea-AI Summary

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech firm, will host a presentation and participate in 1-on-1 investor meetings at Stifel's 2021 Virtual Healthcare Conference on November 15, 2021, at 8:00 AM ET. Dr. Dale Pfost (CEO) and Dr. Adi Mor (CSO) will present. Chemomab specializes in innovative therapeutics for fibrotic and inflammatory diseases, focusing on CM-101, an antibody targeting CCL24. This candidate shows promise in treating severe fibrotic diseases and is currently in Phase 2 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
conferences
-
Rhea-AI Summary

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) has appointed Donald R. Marvin as the new Chief Financial Officer, Executive Vice President, and Chief Operating Officer. With over 35 years of experience in corporate finance and operations, Mr. Marvin aims to utilize his expertise to advance Chemomab's clinical programs. The company is focused on innovative therapeutics for fibrotic and inflammatory diseases, notably its drug CM-101, which is currently in Phase 2 clinical trials for various conditions. The leadership change is seen as a strategic move to enhance Chemomab's growth and operational efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary

Chemomab Therapeutics (Nasdaq: CMMB) announced a webinar featuring Dr. Dinesh Khanna, an expert in systemic sclerosis (SSc), on November 3, 2021. The discussion will cover the treatment landscape and clinical utility of CM-101, a monoclonal antibody targeting CCL24. CM-101 is currently being evaluated in Phase 2 trials for various fibrotic conditions, including SSc. As SSc lacks approved disease-modifying treatments, Chemomab aims to address this unmet medical need with its innovative therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
Rhea-AI Summary

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced a collaboration with Leeds University to study CCL24's role in vascular damage related to systemic sclerosis (SSc), a severe autoimmune condition. Led by Professor Francesco Del Galdo, this partnership aims to deepen the understanding of CCL24's contribution to SSc pathology. Chemomab plans to assess its CCL24-neutralizing monoclonal antibody, CM-101, in a Phase 2 trial in SSc patients starting early next year, building on existing mechanistic data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none

FAQ

What is the current stock price of Chemomab Therapeutics (CMMB)?

The current stock price of Chemomab Therapeutics (CMMB) is $0.96 as of April 8, 2025.

What is the market cap of Chemomab Therapeutics (CMMB)?

The market cap of Chemomab Therapeutics (CMMB) is approximately 19.6M.

What does Chemomab Therapeutics Ltd. specialize in?

Chemomab specializes in developing innovative therapies for fibro-inflammatory diseases, including primary sclerosing cholangitis (PSC) and systemic sclerosis.

What is nebokitug (CM-101)?

Nebokitug is a first-in-class monoclonal antibody that neutralizes CCL24, targeting the inflammatory and fibrotic pathways central to fibro-inflammatory diseases.

What are Chemomab's key clinical advancements?

Chemomab's Phase 2 SPRING trial in PSC demonstrated safety, tolerability, and efficacy across multiple disease biomarkers, paving the way for a Phase 3 trial.

What regulatory designations has nebokitug received?

Nebokitug has been granted Orphan Drug and Fast Track designations by the FDA and EMA for the treatment of PSC.

What is Chemomab's market potential?

Chemomab targets rare diseases with high unmet needs, such as PSC, which affects an estimated 30,000 patients in the U.S. and 80,000 worldwide.

How does Chemomab differentiate itself from competitors?

Chemomab's unique dual-action mechanism of nebokitug and its focus on fibro-inflammatory diseases with no approved therapies set it apart in the biotech landscape.

What are the next steps for Chemomab's clinical programs?

Chemomab plans to launch a Phase 3 registrational trial for nebokitug in PSC in late 2025 and report open-label Phase 2 data in early 2025.

Is Chemomab pursuing strategic partnerships?

Yes, Chemomab is actively engaging with biopharma companies to accelerate development and commercialization timelines for nebokitug.
Chemomab Therapeutics Ltd

Nasdaq:CMMB

CMMB Rankings

CMMB Stock Data

19.61M
14.12M
15.91%
25.92%
2.07%
Biotechnology
Pharmaceutical Preparations
Link
Israel
TEL AVIV